Clay Siegall Continues to Push for New Innovations to Help Patients at Seattle Genetics

A recent post on Clay Siegall’s blog talks about a paralyzed man who is now able to use one of his arms and hand. A system decodes his thoughts and translates into controls for his muscles. The man, Bill Kochevar, was in a bicycle accident and for eight years was unable to move below his shoulders. It was determined that the damage to his spine, prevented signals from his brain from reaching his muscles. Then he had the opportunity to try BrainGate2. The system was trying to connect his brain to his right arm and hand. Electron arrays were placed in Kochevar’s brain and also in the muscles of his arm and hand. The process was a success.

Another post on Clay’s blog talks about how cancer can be attributed to “bad luck.” Researchers Bert Vogelstein and Cristian Tomasetti have suggested that nearly 66 percent of cancers occur randomly. They attribute 5 percent to heredity and 29 percent to environmental factors like smoking, excessive weight, etc. These findings have many asking, “what can be done about this?’, and there is currently no answer. They still claim that 40 percent of cancers are preventable. The question is, how?

Clay Siegall, Ph.D. is a co-founder of Seattle Genetics. He is the President and Chief Executive Officer of the company. He is a scientist with his focus on targeted cancer therapies. He built Seattle Genetics for the purpose of finding and developing drugs and other processes that can help patients. They currently focus on antibody-drug conjugates (ADCs) Their first product ASCETRIS® is now approved in 65 countries. The company is now advancing a pipeline of proprietary ADCs for the treatment of cancer.

Dr. Siegall has help the company enter into several licensing agreements for it technology, including one with Genentech (Roche), AbbVie, and another with GlaxoSmithKline and Pfizer. These agreements have generated $350 million up to this point.